Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was up 7.9% on Monday . The stock traded as high as $0.13 and last traded at $0.13. Approximately 55,583 shares changed hands during trading, a decline of 77% from the average daily volume of 238,157 shares. The stock had previously closed at $0.13.
Bioxytran Trading Up 7.9%
The firm’s 50-day simple moving average is $0.16 and its two-hundred day simple moving average is $0.11. The stock has a market capitalization of $13.51 million, a PE ratio of -13.49 and a beta of 1.82.
Bioxytran (OTCMKTS:BIXT – Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.02) earnings per share for the quarter.
Bioxytran Company Profile
Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
See Also
- Five stocks we like better than Bioxytran
- Consumer Discretionary Stocks Explained
- UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- What Ray Dalio’s Latest Moves Tell Investors
- Compound Interest and Why It Matters When Investing
- Amazon: Why May Is the Last Month to Get the Stock at a Discount
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
